Figure S1. Detection of PD-L1 peptides in long gradient LC-PRM analyses of unfractionated digests from FFPE melanomas.
Figure S2. S1D calibration curves
Figure S3. Spike recovery study for recombinant human PD-L1 100 µg HEK293 cell lysate 0.031, 0.063, 0.125, 0.25, 0.5, 1 or 5 fmol/microgram protein.
Figure S4. MS/MS spectra of PD-L1 LFNVTSTLR peptide and LFDVTSTLR peptide released by PNGase F treatment of recombinant human PD-L1 tryptic digest.
Figure S5. MS/MS spectra of PD-L1 INTTTNEIFYCTFR peptide and L1 IDTTTNEIFYCTFR peptide released by PNGase F treatment of recombinant human PD-L1 tryptic digest.
Figure S6. MS/MS spectra of PD-L1 DLYVVEYGSNMEIECK peptide and L1 DLYVVEYGSDEMEIECK peptide released by PNGase F treatment of recombinant human PD-L1 tryptic digest.
Recomb PD-L1

LFNVTSTLR
m/z 1134.012
Δ = 3.0 ppm

Melanoma B14

Figure S7
Recomb PD-L1

LFNVTSTLR

m/z 1215.0386 (+2)

Δ = 2.9 ppm

Melanoma B14

Figure S8
Recomb PD-L1

LFNVTSTLR
m/z 1296.065 (+2)
Δ = 3.0 ppm

Melanoma B14

Figure S9
Recomb PD-L1

LFNVTSTLR
m/z 1377.0914 (+2)
Δ = 2.5 ppm

Melanoma B14

Figure S10
Recomb PD-L1

Melanoma B14

Figure S11